title: Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.
abstract: Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. Existing literature has reported differences in polymorphism and activity of CYP1A2 in Japanese and non-Japanese ethnic groups, which may alter anagrelide metabolism. We intended to identify the optimum dosage of anagrelide in treatment-naïve Japanese patients with ET and assess its long-term safety and efficacy. Twelve patients with ET and a platelet count of ≥ 80 × 10(4)/μL were enrolled. Anagrelide was administered at an initial dose of 0.5 mg/day (weeks 1-4), then increased to 1.0 mg/day (weeks 5-8). During the following maintenance (weeks 9-52) and continuation periods (weeks 53-104), the dose was adjusted according to patient safety data and to maintain target platelet counts (<60 × 10(4)/μL). Increasing the dose led to a decrease in mean platelet count, and target platelet counts were maintained in 11 patients. Adverse events were mild or moderate, and none led to discontinuation. This cohort of Japanese patients exhibited higher pharmacokinetic exposures of anagrelide and its active metabolite than those previously documented in non-Japanese patients. These differences were modest, suggesting specific dosing regimens for Japanese patients are not required.
authors: School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. okamoto@a7.keio.jp
authors: Shinichiro
authors: S
authors: Okamoto
authors: Yoshitaka
authors: Y
authors: Miyakawa
authors: Jonathan
authors: J
authors: Smith
authors: Ian
authors: I
authors: Hodgson
authors: Brihad
authors: B
authors: Abhyankar
authors: Steven
authors: S
authors: Troy
authors: Yuzuru
authors: Y
authors: Kanakura
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D010976:Platelet Count; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide
references: Semin Thromb Hemost. 1997;23(4):379-83
references: 9263355
references: Acta Neurol Scand. 2000 Nov;102(5):299-302
references: 11083506
references: Neurol Clin. 2002 Feb;20(1):265-81, viii
references: 11754311
references: Cancer. 2004 Nov 15;101(10):2239-46
references: 15476273
references: Br J Haematol. 2010 May;149(3):352-75
references: 20331456
references: Semin Thromb Hemost. 1997;23(4):365-70
references: 9263353
references: Am J Hematol. 2005 Sep;80(1):81-3
references: 16138352
references: Clin Pharmacol Ther. 1981 Mar;29(3):381-6
references: 7471608
references: Blood. 2000 Apr 15;95(8):2514-22
references: 10753829
references: Clin Pharmacol Ther. 2008 Sep;84(3):347-61
references: 18231117
references: N Engl J Med. 1995 Apr 27;332(17):1132-6
references: 7700286
references: Br J Pharmacol. 2005 Oct;146(3):324-32
references: 16041400
references: J Clin Pharmacol. 2002 May;42(5):501-11
references: 12017344
references: Clin Pharmacol Ther. 2008 Sep;84(3):417-23
references: 18615002
references: N Engl J Med. 1988 May 19;318(20):1292-4
references: 3362187
references: N Engl J Med. 2005 Jul 7;353(1):33-45
references: 16000354
references: Am J Med. 1992 Jan;92(1):69-76
references: 1731512
references: Int J Clin Pharmacol Ther. 2012 Nov;50(11):787-96
references: 22943924
references: Blood. 2001 Feb 15;97(4):863-6
references: 11159509
references: J Clin Oncol. 2011 Feb 20;29(6):761-70
references: 21205761
references: Int J Hematol. 2006 Jun;83(5):443-9
references: 16787877